Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

Smedley1 Aug. 4 at 7:48 PM

$TLSA im in….30K shares…thanks to those who helped with their input

0 · Reply

Punk76 Aug. 4 at 2:13 PM

$TLSA in fact he would rather pay out of his own pocket then lose share, just as he has been doing for #Acut that was spun out of #Tlsa

0 · Reply

Punk76 Aug. 4 at 2:08 PM

$TLSA cash position is fine, I've been in this company for 5+years and no call Check out the chairman and board, he's very accomplished and is unlikely to dilute his 30% He has a very good record of bringing on bio companies to success before sale to major

1 · Reply

Smedley1 Aug. 4 at 1:17 PM

$TLSA did quite a bit of research on this…loved everything i saw, but cant find anything about cash runway…when was last offering ? how much cash they have and what is monthly/qrtrly burn ? dilution is always big concern when it comes to bios that arent that close to commercializing any product….thanks in advance

0 · Reply

Ic0gcds000 Aug. 3 at 3:57 PM

$TLSA Big pharma must be thinking about a buyout!!!

2 · Reply

WHATABOUTSTOCKS Aug. 3 at 11:19 AM

$TLSA $4 first target! deal announcement = gap up !

0 · Reply

Holdmybagz Aug. 2 at 10:06 PM

$SPY $TLSA https://www.youtube.com/watch?v=xx8qCWGQDvw

1 · Reply

upsoon007 Aug. 1 at 6:19 PM

$TLSA wouldn‘t mind a little pullback to add more here 😅

0 · Reply

rp6577 Aug. 1 at 1:56 PM

$TLSA healthy clear out there. Will move higher

1 · Reply

Punk76 Aug. 1 at 12:57 PM

$TLSA $3 by end Aug?

1 · Reply

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 11:08 PM EDT - 7 weeks ago

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Jun 13, 2025, 10:30 AM EDT - 7 weeks ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 7 weeks ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 2 months ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 2 months ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 12, 2025, 7:00 AM EDT - 3 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 9, 2025, 7:00 AM EDT - 3 months ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 3 months ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 3 months ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 5 months ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 5 months ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 5 months ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 5 months ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 5 months ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 5 months ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 5 months ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 6 months ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Jan 23, 2025, 3:00 PM EST - 6 months ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025, 8:54 AM EST - 6 months ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Jan 22, 2025, 4:05 PM EST - 6 months ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Jan 8, 2025, 7:00 AM EST - 7 months ago

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Nov 1, 2024, 1:00 PM EDT - 9 months ago

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Oct 30, 2024, 10:29 PM EDT - 9 months ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Appoints New Chief Executive Officer

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Granted FDA Fast Track Designation

Jun 28, 2024, 11:01 AM EDT - 1 year ago

Tiziana Receives $3.4 Million in Non-Dilutive Funding

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab

May 30, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

May 13, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

Apr 25, 2024, 10:00 AM EDT - 1 year ago

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

Apr 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Mar 5, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease

Jan 8, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Jan 5, 2024, 9:30 AM EST - 1 year ago

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

Jan 5, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Dec 19, 2023, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

Dec 4, 2023, 7:09 AM EST - 1 year ago

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

Nov 30, 2023, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

Oct 18, 2023, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab

Oct 13, 2023, 7:00 AM EDT - 1 year ago

Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)

Oct 11, 2023, 7:00 AM EDT - 1 year ago

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

Smedley1 Aug. 4 at 7:48 PM

$TLSA im in….30K shares…thanks to those who helped with their input

0 · Reply

Punk76 Aug. 4 at 2:13 PM

$TLSA in fact he would rather pay out of his own pocket then lose share, just as he has been doing for #Acut that was spun out of #Tlsa

0 · Reply

Punk76 Aug. 4 at 2:08 PM

1 · Reply

Smedley1 Aug. 4 at 1:17 PM

0 · Reply

Ic0gcds000 Aug. 3 at 3:57 PM

$TLSA Big pharma must be thinking about a buyout!!!

2 · Reply

WHATABOUTSTOCKS Aug. 3 at 11:19 AM

$TLSA $4 first target! deal announcement = gap up !

0 · Reply

Holdmybagz Aug. 2 at 10:06 PM

$SPY $TLSA https://www.youtube.com/watch?v=xx8qCWGQDvw

1 · Reply

upsoon007 Aug. 1 at 6:19 PM

$TLSA wouldn‘t mind a little pullback to add more here 😅

0 · Reply

rp6577 Aug. 1 at 1:56 PM

$TLSA healthy clear out there. Will move higher

1 · Reply

Punk76 Aug. 1 at 12:57 PM

$TLSA $3 by end Aug?

1 · Reply

Ic0gcds000 Aug. 1 at 7:31 AM

$TLSA I can see a lot of fish burn on the bbq followed by king prawns then main course of fillet mignon Food for thought😂😂

0 · Reply

BigSqueezeComing Aug. 1 at 3:21 AM

$TLSA PT 3

0 · Reply

Ic0gcds000 Jul. 31 at 9:01 PM

$TLSA added more today It would be rude not to!!

0 · Reply

SouthHaus Jul. 31 at 7:49 PM

$TLSA OT, more or less! I am asking for two things: That the Red Sox trade for a starting pitcher before 6 PM. AND That Rich Parkinson gets to launch his three rockets (from yesterday) in the next twelve minutes!

1 · Reply

_www_larval_com_ Jul. 31 at 7:33 PM

$TLSA just popped 3% higher to 7% (~1Mv) a moment ago, 08/15 options, follow for more volatility.

0 · Reply

TradeHack Jul. 31 at 7:29 PM

$TLSA added at breakout with tight stop .

0 · Reply

User32548888 Jul. 31 at 1:38 PM

Boomers!! $TLSA will cure your Alzheimer! Come it up!!

0 · Reply

rp6577 Jul. 31 at 1:35 PM

$TLSA finally getting noticed out there. People buying as much as they can. This company will be worth billions. $8 price target just for MS indication…. Just think about what the Alzheimer’s indication would be worth… $XBI

2 · Reply

User32548888 Jul. 31 at 1:35 PM

$TLSA Can we print Tiziana as well??

0 · Reply

rp6577 Jul. 31 at 1:32 PM

$TLSA challenge $3 this week?

0 · Reply

upsoon007 Jul. 31 at 11:56 AM

$OKYO this could initiate another leg up, just look at $TLSA a week after the Lucid initiation 😎

2 · Reply

StockScanners Jul. 31 at 12:22 AM

$TLSA Keep watch if this holds above 2.16

0 · Reply

Market Cap	278.10M
Revenue (ttm)	0.00
Net Income (ttm)	-11.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	350,500
Avg Vol	318,816
Day's Range	N/A - N/A
Shares Out	116.85M
Stochastic %K	85%
Beta	-0.58
Analysts	Strong Buy
Price Target	$3.00